Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

SANUWAVE Health, Inc. (SNWV) Receives Patent Protection For Extracorporeal Shock Wave Device, Expands Certain Applications

|Includes: SANUWAVE Health, Inc. (SNWV)

SANUWAVE Health, a shock wave technology company focused on the development and commercialization of biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures, has received a patent issued by the U.S. Patent and Trademark Office entitled "Extracorporeal Shock Wave Device." The patent has a term extending to April 2031.

SNWV's current intellectual property portfolio has 36 patents, issued or pending, relating to focused shock waves in medical and non-medical applications. This most recent claim covers a new extracorporeal applicator, which creates non-invasive advantages for certain applications and expands the company's line of protected products.

"This new patent adds to our intellectual property portfolio," SNWV CEO Joseph Chiarelli stated in the press release. "This new type of applicator can be used for cardiology, endovascular, as well as other applications. Our strategy is to maximize the value of SANUWAVE's shock wave technology - to expand the technology's use into as many applications as possible via this new applicator design."

This new patent protects a special reflector geometry that intersects the focal line of an ellipse at a non-perpendicular angle, differing from existing applicators that use classic reflectors that intersect the focal line of an ellipse only at a perpendicular angle. This unique characteristic eliminates cardiovascular occlusions and atherosclerosis, regardless of vessel dimension. This non-invasive technology will be integrated into the company's future applicators.

For more information, visit

QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit